ConductScience.org, home

Comparison · NCT02271945-sae

MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: serious adverse events. Trial comparisons, record NCT02271945-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02271945-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.40.1180.769wilson
Risk in group 20.20.03620.624wilson
Risk difference, group 1 minus group 20.2-0.310.604newcombe hybrid score
Risk ratio, group 1 over group 220.25615.6log
Odds ratio, group 1 over group 22.670.15845.1log
Number needed to harm, for one more participant with a serious adverse event on MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg than on MEDI-551 12 mg/kg and MEDI0680 10 mg/kg5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg
Participants received IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
25EG000
Group 2MEDI-551 12 mg/kg and MEDI0680 10 mg/kg
Participants received IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
15EG001

Harm

What it counts
Total, serious adverse events
Time frame
From treatment administration to 90 days after last dose of study drug (up to approximately 2 years)

Source ClinicalTrials.gov

Trial

Title
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
NCT number
NCT02271945
Phases
PHASE1, PHASE2
Conditions
Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions
MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
Lead sponsor
MedImmune LLC
Results first posted
2018-03-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02271945-sae